Elsevier

Phytomedicine

Volume 8, Issue 4, 2001, Pages 252-261
Phytomedicine

Double-blind, placebo-controlled, randomised cross-over clinical trial of NIPRISAN® in patients with Sickle Cell Disorder

https://doi.org/10.1078/0944-7113-00040Get rights and content

Summary

The study was undertaken to determine the safety and efficacy of NIPRISAN®, a phytomedicine, developed for the management of patients with Sickle Cell Disorder (SCD). The study design is a placebo-controlled double blind cross-over trial. Eighty-two (82) patients with SCD were recruited and randomised into two groups. An initial 4 month pre-trial study was undertaken to determine the similarity of the groups. The main study was conducted over a twelve-month period with cross-over at six months. Safety of the drug was assessed clinically and biochemically.

NIPRISAN® significantly (P < 0.01) reduced the frequency of SCD crisis associated with severe pains. Acute toxicity to the liver assessed by the activities of liver enzymes, indicate that NIPRISAN® is safe. Renal function assessed by the serum levels of creatinine and blood urea nitrogen remained normal.

Both the clinical and laboratory results of the present phase IIB (pivot) clinical study suggest that NIPRISAN® is a safe and efficacious phytomedicine for the management of patients with Sickle Cell Disorder.

References (12)

  • A. Awodogan et al.

    Acute and Short term toxicity of NIPRISAN® in rats. I: biochemical study

    J. Pharm. Res. and Dev.

    (1996)
  • Clinical Alert National Heart, Lung and Blood Institute, NIH. 13:26; 003. 10, Feb...
  • C.E. Effiong

    Sickle Cell Disease in Childhood

  • W.R. Faulkner et al.

    Renal Function

  • K. Gamaniel et al.

    Pharmacological Profile of NIPRD 94/002/1–0: A Novel Herbal Antisickling Agent

    J. Pharm. Res. And Dev.

    (1998)
  • F.E.A. Lesi
There are more references available in the full text version of this article.

Cited by (80)

  • Functional foods: promising therapeutics for Nigerian Children with sickle cell diseases

    2022, Heliyon
    Citation Excerpt :

    Eugenia caryophyllata and Piper guineense are other examples of medicinal plants thatcontain vanilloids like Shikimic acid and cannaboids that are of benefit in reducing the painful symptoms of SCD [126]. Additional phytomedicines that have been reported to possess antisickling potentials are Pterocarpa osun, Justicia secunda, and Sorghum bicolor extracts [127,128]. Taken together, these functional foods can be used in the form of food or decoction.

  • Time for African youth in science

    2022, Acta Tropica
    Citation Excerpt :

    In Togo, people use DREPANOSTAT® (also a mixture of Z. zanthoxyloïdes and C. procera) against the sickle cell anemia (Villaret et al., 2018). In Nigeria, the treatment proposed is NIPRISAN® (Piper guineenses seeds, Pterocarpus osun stem, Eugenia caryophylum fruit and Sorghum bicolor leaves) (Wambebe, 2001). Formulation can be performed in Africa with companies such as the Nigerian pharmaceutical company May & Bake which formulates the NIPRISAN®.

  • A highly sensitive UPLC-MS/MS method for hydroxyurea to assess pharmacokinetic intervention by phytotherapeutics in rats

    2020, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
    Citation Excerpt :

    In this direction, plants based natural products, including amino acids for adjuvant/supplementation therapy, have been explored in the preclinical/clinical model to elucidate their beneficial role for the symptomatic management of SCA. Representative examples of such phytochemical/botanical drug are L-arginine [9], caricapinoside [10], resveratrol [11], curcumin [12], docosahexaenoic acid/omega-3 fatty acid [13], gum arabic [14], SCD-101 [15], NIPRISAN [16], and so on. Therefore, we would like to identify phytochemicals that can’t hinder the pharmacokinetics of HU and at the same time those compounds have the useful pharmacological effects to combat with the side effects associated with HU therapy.

  • Advances in the Treatment of Sickle Cell Disease

    2018, Mayo Clinic Proceedings
    Citation Excerpt :

    Part B of this phase 1b clinical trial is a randomized, double blind, placebo-controlled crossover study of SCD-101 in patients with SCA and is currently recruiting (NCT02380079). Another antisickling agent with an unknown mechanism of action, Nicosan (or Niprisan) is a plant extract shown to decrease painful crises in Nigerian patients.63,64 There are no trials studying Niprisan in the United States.

  • Treating sickle cell disease by targeting HbS polymerization

    2017, Blood
    Citation Excerpt :

    Among the drugs listed as antisickling agents is SCD-101, a plant extract similar to Niprisan (Nix-0699). Niprisan is an ethanol-water extract from the seeds, stems, fruit, and leaves of 4 different plants, has been used among diverse populations in Nigeria, and has been reported to be effective in lowering the frequency of pain crises in sickle cell patients.97,98 Niprisan inhibits in vitro sickling and increases both the solubility and delay time of solutions of deoxy-HbS, albeit in a highly nonphysiological buffer.99

View all citing articles on Scopus
View full text